Core Insights - Health Catalyst reported revenue of $80.72 million for the quarter ended June 2025, reflecting a 6.4% increase year-over-year, and an EPS of $0.04, down from $0.12 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $80.53 million by 0.24%, while the EPS surpassed the consensus estimate of $0.03 by 33.33% [1] Revenue Breakdown - Professional services revenue was $27.85 million, slightly below the average estimate of $27.86 million, representing a year-over-year decline of 1.5% [4] - Technology revenue reached $52.88 million, exceeding the estimated $52.67 million, and showing an 11% increase compared to the previous year [4] Profitability Metrics - Adjusted Gross Profit for Professional Services was reported at $5.11 million, surpassing the average estimate of $4.09 million [4] - Adjusted Gross Profit for Technology was $34.85 million, slightly below the average estimate of $35.35 million [4] Stock Performance - Over the past month, Health Catalyst shares have returned -5.2%, contrasting with a +1.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]

Financial Data and Key Metrics Changes - The company reported Q2 2025 revenue of $80.7 million, representing a 6% year-over-year increase and exceeding guidance [31] - Adjusted EBITDA for Q2 2025 was $9.3 million, the highest in the company's history, and also above guidance [34] - The company revised its full-year 2025 revenue guidance to $310 million due to significant impacts from Medicaid and research funding cuts [6][7] - Adjusted gross margin for Q2 2025 was 50%, a decrease of approximately 30 basis points year-over-year [32] Business Line Data and Key Metrics Changes - Technology segment revenue for Q2 2025 was $52.9 million, reflecting an 11% year-over-year growth driven by recurring revenue from new and acquired clients [32] - Professional services revenue for Q2 2025 was $27.8 million, a 1% decline compared to Q2 2024 [32] - Adjusted technology gross margin was 66%, down approximately 140 basis points year-over-year, while adjusted professional services gross margin was 18%, down approximately 190 basis points year-over-year [32][34] Market Data and Key Metrics Changes - The company anticipates that the impacts of Medicaid and research funding cuts will be a headwind not only in 2025 but likely over the next few years [13] - The company has seen delays in signing new platform client contracts due to macroeconomic uncertainty and funding cuts [9][12] Company Strategy and Development Direction - The company is focused on improving profitability and has removed its previously shared 2028 revenue target of $500 million, emphasizing near-term profitability improvements [14] - The strategic focus is on expanding applications revenue, which has been growing at over 20% year-over-year, and leveraging the Ignite platform for cross-selling opportunities [16][17] - The company plans to complete the migration of platform clients to Ignite by mid-2026, which is expected to alleviate some revenue headwinds [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term strategy despite current macroeconomic challenges, including inflation and funding cuts [6][14] - The company expects to maintain adjusted EBITDA guidance of $41 million for 2025, despite the revenue reduction [21] - Management acknowledged the need for clients to adjust to new funding realities, which may take time [52] Other Important Information - The company announced a restructuring plan that will impact approximately 9% of its workforce, aimed at improving profitability by over $40 million annually [20] - A new director, Justin Spencer, will join the board effective September 1, bringing relevant experience from the healthcare technology sector [29] - The CEO announced plans to retire effective June 30, 2026, after 15 years in the role [30] Q&A Session Summary Question: How is the Life Science business performing and what level of investment is needed for growth? - Management noted delays in late-stage opportunities in the CareVive business due to research funding cuts but remains confident in the differentiated offering [41][42] Question: Can you explain the market reaction to the recent Medicaid cuts? - Management highlighted a conservative approach among not-for-profit clients, which has led to delays in project initiation as they adjust to funding cuts [50][51] Question: What is the expected EBITDA for 2026? - Management indicated a run rate of approximately $60 million of adjusted EBITDA going into 2026, with potential for additional operating leverage [52][54] Question: What is the contribution of app layer client wins versus external client wins for new platform clients? - Approximately two-thirds of new platform clients have come from existing clients, reflecting strong cross-sell momentum [58][59] Question: How should investors think about growth rates for 2026 and beyond? - Management suggested that growth may be in the low single digits for 2026 due to ongoing macro headwinds, but expects a return to growth as the Ignite migration is completed [66][71]

Core Insights - Doximity is enhancing its capabilities in artificial intelligence by acquiring Pathway Medical for $63 million, aiming to improve its platform for healthcare professionals [1][4] - Pathway Medical has developed an AI-powered clinical reference tool that provides answers to medical questions based on a large structured dataset, which Doximity intends to integrate into its services [2][3] - The acquisition is expected to allow Doximity's platform to serve as a resource for doctors seeking clinical answers, expanding its functionality beyond networking and administrative tasks [3][4] Financial Details - The acquisition deal closed in late July, involving a cash payment of $26 million and potential additional equity grants of up to $37 million [4] Integration and Development - Doximity is actively integrating Pathway's technology, with testing of a combined product already underway involving thousands of doctors [4]

Hackers have stolen login credentials from thousands of people working with the UK’s National Health Service, putting the organization at risk of further cyberattacks, researchers say https://t.co/KmriZpmEfV ...

Core Insights - The U.S. market experienced a slight decline as investors reacted to new earnings reports, economic data, and tariff announcements, particularly regarding semiconductor and pharmaceutical imports [1] - In the current environment characterized by geopolitical risks and policy changes, value investing is highlighted as a favorable strategy, focusing on purchasing undervalued stocks [1] Investment Strategy - Value investing involves buying stocks priced below their intrinsic value, capitalizing on market mispricing to achieve future profits [1] - Earnings yield is a key metric for value investors, calculated as (Annual Earnings per Share/Market Price) x 100, serving as a reverse indicator of the price-to-earnings (P/E) ratio [3] - A high earnings yield suggests a stock may be undervalued, while a low yield indicates potential overvaluation [3] Stock Selection Criteria - An earnings yield greater than 10% is set as a primary screening criterion, supplemented by additional parameters [5] - Estimated EPS growth for the next 12 months must be greater than or equal to the S&P 500, comparing forward EPS estimates with actual EPS [5] - Average daily trading volume over the past 20 days should be at least 100,000, indicating sufficient liquidity [6] - Current stock price must be $5 or higher, and stocks with a Zacks Rank of 1 (Strong Buy) or 2 (Buy) are expected to outperform peers [7] Highlighted Stocks - Barrick Mining Corporation is a leading gold mining company with projected earnings growth of 56% and 24% for 2025 and 2026, respectively, and a Zacks Rank of 1 [8] - Astrana Health, a tech-enabled healthcare provider, anticipates earnings growth of 77% and 49% for 2025 and 2026, respectively, also holding a Zacks Rank of 1 [9][10] - StoneCo Ltd., a fintech company, expects earnings growth of 10.4% and 16% for 2025 and 2026, with a Zacks Rank of 1 [11] - Plains GP Holdings, involved in crude oil transportation and marketing, projects earnings growth of 206% and 24% for 2025 and 2026, respectively, and has a Zacks Rank of 1 [12] - PHINIA Inc., a supplier for the mobility industry, forecasts earnings growth of 14% and 19.5% for 2025 and 2026, respectively, and holds a Zacks Rank of 1 [13]

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $70.9 million, a 13% increase compared to Q2 2024. Normalizing for the sale of Amwell Psychiatric Care, revenue was 25% higher year-over-year [20] - Subscription software revenue accounted for 57% of total revenue at $40.4 million, up 47% from a year ago [20] - Adjusted EBITDA for the quarter was a negative $4.7 million, significantly improved from a negative $35 million in Q2 2024 [26] - Cash burn was reduced to $3 million in Q2, with $219 million in cash and marketable securities and zero debt [26] Business Line Data and Key Metrics Changes - Amwell Medical Group (AMG) visit revenue was $22.8 million, down 20.8% year-over-year, but visits were flat when normalizing for the sale of APC [21] - Average revenue per visit was $73, which is 9% lower compared to last year, but 8.3% higher when normalizing for the APC sale [22] - Services and CarePoint revenue was $7.7 million, slightly down from $8 million in the previous quarter [23] Market Data and Key Metrics Changes - Approximately 1.2 million visits were completed in Q2, a decrease of 22.3% year-over-year [21] - The company is experiencing a shift towards technology-enabled care, with increasing consumer demand for online healthcare services [15] Company Strategy and Development Direction - The company aims to achieve positive cash flow from operations by 2026, focusing on expanding subscription software revenues and reducing costs [6][27] - Amwell is leveraging artificial intelligence as a key driver for healthcare modernization and efficiency [7][17] - The company is committed to enhancing its role in the federal market and expanding its client base through strategic partnerships [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing transformation of healthcare towards technology-enabled solutions, emphasizing the importance of cost reduction and improved clinical outcomes [7][15] - The company anticipates that the current market dynamics will favor its growth strategy, particularly in the government sector [18] Other Important Information - The 2026 contract extension with the military health system excluded behavioral health and automated care programs due to budget restrictions [11] - The company is targeting a 60% improvement in adjusted EBITDA for 2025 compared to 2024 [14] Q&A Session Summary Question: Can you share how the revenue run rate of the extended DHA contract compares to the pilot contract? - The annualized value of the extended contract is slightly greater than the previous pilot contract, indicating a small increase in revenue [39] Question: Does the expected subscription revenue for 2025 indicate a decline? - The decrease in expected subscription revenue is primarily due to the exclusion of automated care and behavioral health from the DHA contract extension [44] Question: How does the company plan to achieve cash flow breakeven by 2026? - Achieving breakeven will involve focusing on modern platforms, reducing costs, and leveraging AI to enhance operational efficiency [46] Question: What is the impact of the DHA contract on behavioral and automated care? - The exclusion of these programs is related to budget constraints rather than their effectiveness, and there is optimism for their future inclusion [51] Question: How do third-party clinical solutions affect gross margins? - Integrating third-party solutions into Amwell's platform enhances patient engagement and reduces customer acquisition costs, contributing positively to gross margins [72] Question: Are there any changes in the sales cycle due to macroeconomic factors? - The focus has shifted towards cost savings, which has not negatively impacted the sales cycle; in fact, it may have accelerated it [75]

Financial Results Announcement - Medtronic plc will report its financial results for the first quarter of fiscal year 2026 on August 19, 2025, following the end of the quarter on July 25, 2025 [1] - The company plans to announce results for the subsequent quarters on November 18, 2025, February 17, 2026, and May 20, 2026 [1] Company Overview - Medtronic is a leading global healthcare technology company headquartered in Galway, Ireland, with over 95,000 employees across more than 150 countries [2] - The company's mission is to alleviate pain, restore health, and extend life, addressing 70 health conditions through various technologies including cardiac devices, surgical robotics, and patient monitoring systems [2] - Medtronic aims to deliver innovative technologies that transform lives, impacting two people every second [2]

Core Viewpoint - Amwell, a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, announced its financial results for the second quarter ended June 30, 2025 [1] Group 1: Financial Results - The second quarter earnings report for Amwell is available for review on their investor relations website [1] - A conference call to discuss the financial results is scheduled for today at 5 p.m. ET, accessible via a live audio webcast [2] Group 2: Company Overview - Amwell offers a single, comprehensive, technology-enabled care platform for payers and health systems, enhancing patient access to convenient, affordable, and effective care [3] - The platform includes software and services that support various clinical programs, providing unified and personalized access to diversified clinical programs across the care continuum [3] - Amwell has been operational for almost two decades, serving some of the largest healthcare organizations in the U.S. and globally, demonstrating its capability to deliver dependable outcomes at scale [3]

Financial Data and Key Metrics Changes - The company achieved record quarterly revenue of $74.4 million, up 4% from the same quarter last year [6][24] - Operating income increased by 33.4% to $5.9 million, while net income rose by 29.3% to $5.4 million [6][25] - Adjusted EBITDA was reported at $17.6 million, reflecting an 11.3% increase [6][29] - Subscription product revenues grew by 4.2%, while professional service revenues declined by 3.5% [25] Business Line Data and Key Metrics Changes - Credential Stream revenue grew by 26%, Shift Wizard by 21%, and Competency Suite by 18% [26] - Legacy products in credentialing and scheduling saw a decline totaling $1.8 million compared to last year [26] - Excluding legacy products, the core business grew over 8% in the quarter [26] Market Data and Key Metrics Changes - Remaining performance obligations were $618 million, up from $538 million year-over-year, with expectations of 39% conversion to revenue in the next 12 months [26] - The company maintains a strong cash balance of $90.6 million and has no interest-bearing debt [23][29] Company Strategy and Development Direction - The company is transitioning from SaaS applications to a PaaS architecture to enhance interoperability [21] - HealthStream is focused on utilizing AI to improve efficiency and create competitive differentiation across its product offerings [13][14] - The launch of the HealthStream Learning Experience (HLX) aims to provide personalized self-directed learning pathways for healthcare professionals [17][39] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the sales pipeline and macroeconomic conditions, noting that four out of five anticipated deals were signed in the second quarter [8][52] - The company is well-positioned to help customers navigate new healthcare policies and improve workflow efficiency [51][52] - Management anticipates continued growth in healthcare employment over the next five years despite some challenges in specific segments [78][80] Other Important Information - The company holds 20 patents and has received over 40 Brandon Hall awards for excellence in learning and development [22] - A quarterly cash dividend of 3.1 cents per share was declared, to be paid on August 29 [33] Q&A Session Summary Question: Will gross margins bounce back in Q3? - Management expects gross margins to hover around 65% for the remainder of the year due to ongoing costs related to scaling and performance improvements [58][59] Question: What does the pipeline look like for the HLX platform? - The HLX is now a revenue-generating product, and the company is beginning to build a pipeline for it, expecting steady incremental growth [60][61][62] Question: Can you elaborate on Shift Wizard and legacy products? - The growth of Shift Wizard is now surpassing the decline of legacy products, and the offset from legacy products is expected to diminish in the coming quarters [68][70] Question: Was there any reputational damage from the scaling issues in CredentialStream? - While there was some frustration among customers, management believes the impact will be minimal and is focused on improving capacity and service [73][76] Question: How does the healthcare employment market impact HealthStream? - Overall healthcare employment is expected to grow, and while there may be challenges in specific segments, the demand for healthcare services remains strong [78][80] Question: How are price escalators being integrated into contracts? - Price escalators are being included in new and renewed contracts, and negotiations are generally reasonable [87][88] Question: Can you provide an update on NurseGrid's performance? - NurseGrid is generating over $50,000 a month in revenue through its new monetization strategies, and the user base continues to grow [90][93]

Q2 2025 Performance Highlights - Net income increased by 73%[20] - Free cash flow increased by 102%[20] - Earnings per share became positive for the first time[20] Financial Results - Q2 2025 revenue was $27.4 million compared to $28.1 million in Q2 2024[43] - Q2 2025 net income was $2.9 million compared to $1.7 million in Q2 2024[43] - Q2 2025 adjusted EBITDA was $6.5 million compared to $6.4 million in Q2 2024[43] - Q2 2025 earnings per share was $0.04 compared to -$0.14 in Q2 2024[43] - Q2 2025 free cash flow was $5.4 million compared to $2.7 million in Q2 2024[43] - Year-to-date 2025 revenue was $55.0 million compared to $54.1 million in year-to-date 2024[46] - Year-to-date 2025 net income was $4.9 million compared to $1.4 million in year-to-date 2024[46] - Year-to-date 2025 adjusted EBITDA was $12.1 million compared to $10.1 million in year-to-date 2024[46] - Year-to-date 2025 earnings per share was $0.02 compared to -$0.24 in year-to-date 2024[46] - Year-to-date 2025 free cash flow was $9.0 million compared to $4.9 million in year-to-date 2024[46] 2025 Guidance - Revenue guidance is $111 million to $114 million[27] - Adjusted EBITDA guidance is $26 million to $28 million[27] - Earnings per share guidance is $0.10 to $0.13[27]